araag2/HINT huggingface dataset:
Clinical trial NCT02222441 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: palbociclib alone, palbociclib plus modafinil, palbociclib alone, palbociclib plus pioglitazone
SMILES: CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O, [Na+].CC([O-])=O, CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O, [Na+].CC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and/or female subjects of non childbearing potential between the ages of
             18 and 55 years, inclusive.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  Subjects with a self-reported history of addiction, especially to stimulants.

          -  A positive urine drug screen or alcohol breath test.

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential; male subjects with partners currently pregnant; male subjects
             of childbearing potential who are unwilling or unable to use a highly effective method
             of contraception as outlined in this protocol for the duration of the study and for 90
             days after the last dose of investigational product.
Clinical trial NCT02227329 (phase 1/phase 2, status: terminated)
Conditions: catheter-related bloodstream infection (crbsi) nos, bloodstream infection due to central venous catheter, bloodstream infection due to hickman catheter
ICD codes: T80.211S, T80.211A, T80.211D, T80.211S, T80.211A, T80.211D, T80.211S, T80.211A, T80.211D
Drugs: ethanol, heparin lock, normal saline
SMILES: NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, O
Reason stopped: 
    publication of guidelines advising against the use of ethanol locks.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Newly started on Home parenteral Nutrition and anticipated duration >3 months.

          -  Not previously on Home Parenteral Nutrition.

          -  Providing consent.

          -  Patients with non-medicare insurance.

          -  Patients with medicare insurance and a supplementary insurance.

          -  Patients with single lumen Hickman® catheters.

          -  No known alcohol addiction.

        Exclusion Criteria:

          -  Failure to provide consent

          -  Patients with medicare insurance and no other supplemental private insurance

          -  Patients with a catheter type other than a single lumen Hickman®

          -  Patients who are on HPN for less than three months

          -  Pregnant patients

          -  Patients who have previous proven addiction and dependence to alcohol.

          -  Patients lacking capacity to provide consent

          -  Patients who are not be managed by HPN team at investigator's institution
Clinical trial NCT02231658 (phase 1, status: terminated)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: liraglutide, lixisenatide
SMILES: CN(C)C(=N)NC(N)=N, [V].[H][C@](C)(O)[C@]([H])(N=C(O)CN=C(O)[C@]([H])(CCC(O)=O)N=C(O)CN=C(O)[C@@]([H])(N)CC1=CN=CN1)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCSC)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(O)=N)C(O)=NCC(O)=NCC(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@@]([H])(C)C(=O)N1CCC[C@@]1([H])C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N)[C@@]([H])(C)CC)[C@@]([H])(C)O
Reason stopped: 
    too challenging to recruit appropriate participants at an acceptable speed.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial.

          -  Male or female aged 18-65 years (both inclusive)

          -  T2DM diagnosis

        Exclusion Criteria:

          -  Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics

          -  Use of GLP-1 mimetics or DPP-IV inhibitors

          -  Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%
Clinical trial NCT02238717 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: pf-06372865 (65mg), pf-06372865 (15mg), pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG or clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug screen.
Clinical trial NCT02249871 (phase 1, status: completed)
Conditions: diabetes, healthy
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, Z76.3, Z76.2
Drugs: semaglutide, omeprazole
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, [Na+].OC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female age 18-75 years (both inclusive) at time of signing informed consent

          -  Body mass index of 18.5-29.9 kg/m^2 (both inclusive)

          -  A good general health based on medical history, physical examination, and results of
             vital signs, electrocardiogram and laboratory safety tests performed during the
             screening visit, as judged by the investigator

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using adequate contraceptive methods. Female of child
             bearing potential must use effective methods of birth control for the duration of the
             trial and for 5 weeks following last dose. Only highly effective methods of birth
             control are accepted (i.e., one that results in a less than 1% per year failure rate
             when used consistently and correctly, such as implants, injectables, combined oral
             contraceptives, and some intrauterine devices)

          -  History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease

          -  Hypertension (defined as sitting systolic blood pressure above or equal to 140 mmHg
             and/or diastolic blood pressure above or equal to 90 mmHg). If white-coat hypertension
             is suspected at the screening visit a repeated measurement is allowed

          -  Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in
             excess of 400 mL within the 3 months preceding screening
Clinical trial NCT02253212 (phase 1/phase 2, status: completed)
Conditions: glioblastoma, glioma, brain tumor
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6
Drugs: carboplatin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Age greater than 18 years.

          -  Subjects with recurrent glioma who have failed standard therapy with surgery and/or
             treatment with radiation and temozolomide.

          -  Patient eligible for Carboplatin-based chemotherapy

          -  Contrast-enhanced tumor less than 35 mm in diameter

          -  No risk of cerebral herniation

          -  Able to tolerate pre/post procedure steroid treatment

          -  Social security affiliated (in France)

          -  Able and willing to give signed and informed consent

          -  Normal biological status

          -  Hemoglobin ≥ 10 g/dl

          -  Platelets ≥ 100000/mm3

          -  Neutrophils ≥ 1500/mm3

          -  Normal creatine clearance ≥ 60ml/mn

          -  ASAT < 3 N

          -  ALAT < 3 N

          -  Normal Bilirubin Level < 1.5 N

          -  Alkaline Phosphatase < 3 N

          -  INR < 1.5

          -  Prothrombin Level ≥ 70%

        Exclusion criteria:

          -  Allergic to Iodine, Gadolinium, Xylocain

          -  Contra-indications to echographic contrast agent (microbubbles)

          -  Severe Renal insufficiency

          -  Hepatic insufficiency

          -  Possible toxic treatment for CNS

          -  Previously infected surgical field

          -  Uncontrolled epilepsy

          -  MRI contra-indications

          -  Hemostasis troubles thrombopenia <75.000, TP <60%, INR >1.5, anti-platelet or
             anticoagulant therapy on-going)

          -  Active phlebitis or active pulmonary embolism

          -  Pregnant or currently breast-feeding

          -  Patients under judicial protection
Clinical trial NCT02253277 (phase 1, status: completed)
Conditions: chronic myeloid leukemia
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: nilotinib, ruxolitinib
SMILES: CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F, N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Eligibility criteria:

        Inclusion Criteria:

        Patients of the first stratum must have chronic myeloid leukemia receiving nilotinib
        first-line therapy or receiving second-line or subsequent-line treatment with nilotinib.

        Patients of the second stratum must have CML in AP/BC or relapsed/refractory Ph+ ALL, or be
        Ph+ ALL patients with MRD with or without prior nilotinib pretreatment;

        Patients must have adequate end organ function, as defined by:

          -  Creatinine < 2.0 x upper limit of normal (ULN)

          -  Total bilirubin < 1.5 x ULN (< 3.0 x ULN if related to disease or polymorphism, such
             as Mb. Gilbert)

          -  ALT and AST < 2.5 x ULN (< 5.0 x ULN if related to disease)

          -  Serum lipase ≤ 1.5 x ULN

          -  Alkaline phosphatase ≤ 2.5 x ULN (< 5.0 x ULN if related to disease);

        Patients must have the following electrolyte values within normal limits or corrected to
        within normal limits with supplements prior to the first dose of study medication:

          -  Potassium

          -  Magnesium

          -  Phosphate

          -  Total calcium (corrected for serum albumin);

        Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test
        within 7 days before initiation of study drug. All WOCBP must use highly effective
        contraceptive methods throughout and during 3 months after study;

        Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 for
        patients in CP, ≤ 2 for patients in AP/BC or with relapsed/refractory Ph+ ALL or with Ph+
        ALL with MRD;

        Patient has the following laboratory values within 7 days of starting study drug:

        - For CML and Ph+ ALL patients: platelet count > 75 x 109/L and ANC > 1.0 x 109/L

        Exclusion Criteria:

        Patient must not have evidence of active malignancy other than the existing CML or ALL

        Patient must not receive drugs that interfere with coagulation or inhibits platelet
        function, with the exception of aspirin ≤ 150 mg per day or low molecular weight heparin.

        Patient must not have history of platelet dysfunction, bleeding diathesis, and/or
        coagulopathy in the 6 months prior to screening;

        Patient must not require treatment with any strong CYP3A4 inducer or inhibitor

        Patient must not have history of hypersensitivity to any of the study drugs or to drugs of
        similar chemical classes and their excipients;

        Patients must not take other investigational drugs within 28 days prior to screening;

        Patient must not be pregnant or lactating at screening and/or baseline;

        Patient must not have impaired cardiac functions

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT02254161 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: matching placebo, bi 1181181 healthy elderly, bi 1181181 healthy young
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion criteria:

          1. Healthy male or female subjects according to the investigator's assessment, based on a
             complete medical history including a physical examination, vital signs (BP, PR),
             12-lead ECG, and clinical laboratory tests.

          2. Age of 18 to 50 years (incl.) for young healthy volunteers or of 65 to 80 years
             (incl.) for elderly healthy volunteers.

          3. BMI of 18.5 to 29.9 kg/m2 (incl.)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation.

        Exclusion criteria:

          1. Any finding in the medical examination (including BP, PR or ECG) is deviating from
             normal and judged as clinically relevant by the investigator

          2. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          3. Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          5. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial
             medication (except appendectomy)

          6. Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders
Clinical trial NCT02265367 (early phase 1, status: completed)
Conditions: tobacco use disorder
ICD codes: Z72.0, P04.2
Drugs: levomilnacipran, placebo
SMILES: CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be between 25 years old and 55 years old

          -  Smoke a minimum number of cigarettes per day

          -  Indicate motivation to quit smoking

        Exclusion Criteria:

          -  Current or history of medical or psychiatric conditions that could interfere with
             measures being studied or that could be affected by the study medication

          -  Use of medication that could interfere with measures to be studied or that could be
             expected to interact with levomilnacipran

          -  Are pregnant or breast feeding

        The investigators will evaluate if there are other reasons why someone may not be eligible
        to participate
Clinical trial NCT02268851 (phase 1, status: active, not recruiting)
Conditions: chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: tgr-1202, ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL),
             or Small Lymphocytic Lymphoma (SLL)

          -  Adequate organ system function ( Absolute neutrophil count, Platelets,Bilirubin,
             Platelets, Aspartate transferase ,Alanine aminotransferase, Creatinine Clearance)

          -  Eastern Cooperative Group (ECOG) Performance status ≤ 2

          -  Ability to swallow and retain oral medication

          -  Female patients: must have negative serum pregnancy test at study screening/ all male
             partners must consent to use a medically acceptable method of contraception

          -  Willingness and ability to comply with trial and follow-up procedures, and give
             written informed consent

        Exclusion Criteria:-

          -  Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy,
             immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization)
             within 3 weeks of Cycle 1/Day 1,

          -  Autologous hematologic stem cell transplant within 3 months of study entry.

          -  Allogeneic hematologic stem cell transplant within 12 months.

               -  Post-allo patients must not have active graft versus-host disease

          -  Evidence of active Hepatitis B,Hepatitis C or HIV infection.

          -  Active central nervous system involvement by lymphoma

          -  Requires treatment with strong CYP3A4/5 inhibitors

          -  Severe and/or uncontrolled medical conditions or other conditions that could affect
             their participation in the study

          -  QTcF >470 msec (QT interval, Fredericia calculation)

          -  Angina not well-controlled by medication

          -  Poorly controlled or clinically significant atherosclerotic vascular disease

          -  Presence of other active cancers, or history of treatment for invasive cancer within
             the past 2 years.

          -  Require warfarin for anticoagulation

          -  Women who are pregnant or lactating
Clinical trial NCT02269566 (phase 1, status: terminated)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: hollisterstier, normal saline
SMILES: O
Reason stopped: 
    the number of enrolled subjects did not meet the goal during the study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Allergic rhinitis to house dust mite (Df, Dp), cat or dog

          -  More than 3mm reaction at skin prick test for Df, Dp, cat or dog or more than class 3
             at serum specific IgE level (UNICAP or MAST)

        Exclusion Criteria:

          -  Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA)
             guideline

          -  FEV1 less than 50% of predicted value if there is comorbid asthma.

          -  Subject rejects the enrollment into study

          -  Low compliance

          -  Pregnancy or lactation

          -  Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious
             diseases

          -  Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic
             antidepressant, immnosuppressant including systemic glucocorticosteroid (20mg or more
             dose of prednisolone or equivalent dose of other steroid) within last 2 weeks

          -  Prior history of allergen-specific immunotherapy

          -  Allergic rhinitis caused by other perennial or seasonal allergen

          -  Vulnerable volunteer
Clinical trial NCT02275065 (phase 1, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: bictegravir, placebo
SMILES: OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  No current or prior anti-HIV treatment, including ART medications received for
             prevention (preexposure prophylaxis [PrEP]), or postexposure prophylaxis (PEP) within
             12 weeks of screening

          -  Plasma HIV-1 ribonucleic acid (RNA) ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at
             screening

          -  Cluster of differentiation 4+ (CD4+) cell count > 200 cells/mm^3

        Key Exclusion Criteria:

          -  Anticipated to start HIV-1 therapy during the study period

          -  Active participation in another study of investigational or approved ART agents

          -  A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within
             the 30 days prior to screening

          -  Participants with positive hepatitis C antibody at screening

          -  Chronic hepatitis B virus (HBV) infection

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.